CClinicalTrials.gg
RecruitingNCT07259174Undated 2Updated Dec 2, 2025

Ultrasound of the Diaphragm Excursion Ratio as Physiological Biomarker in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

An observational study in COPD, sponsored by Isala. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Isala · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
186
Ages
18 Years and older
Sex
All
01

Study summary

3.1 Introduction and rationale In 2020 an estimate of 562.700 people had Chronic Obstructive Pulmonary Disease (COPD) in the Netherlands, resulting in 21.335 hospital admissions.[1] An acute exacerbation COPD (AECOPD) in combination with hospital admission is associated with high mortality and morbidity. [2]

Noninvasive ventilation (NIV) has been very effective in the context of AECOPD, since it efficiently offloads respiratory muscles and counteracts dynamic hyperinflation. This method often prevents intubation as a bridge to administering effective therapies (e.g., glucocorticoids, bronchodilators, and antibiotic agents)[3], and may reduce mortality.[4] Current guidelines recommend NIV for the treatment of acute respiratory failure in patients with respiratory distress, pH \< 7.35, and PaCO2 > 6 kPA (with exclusion of patients requiring invasive ventilation, see guideline).[5,6] National guidelines do not recommend NIV in AECOPD with increased work of breathing without respiratory acidosis due to lack of evidence. [5]

Ultrasound of the diaphragm can identify atrophy and impaired motion or contractility of the diaphragm[10], and has been shown to predict mortality and NIV failure during NIV treatment for respiratory acidosis due to AECOPD.[11-15] Whether ultrasound of the diaphragm may predict mortality or need for (non-)invasive ventilation in AECOPD without respiratory acidosis on initial presentation is unknown.

During exploratory analysis of a previous study (unpublished; NCT05671198) we might have found a marker that has the potential to predict progression to NIV or death during hospitalization for AECOPD without respiratory acidosis:

The difference between diaphragm motion during tidal breathing and maximal breathing, used as a surrogate for inspiratory reserve volume (IRV), was significantly lower in patients requiring NIV or who died in-hospital compared to those who did not (1.59 cm, SD 1.91 vs. 3.14 cm, SD 2.45; p = 0.033). We performed a ROC curve analysis to assess the predictive value of these variables, which yielded an area under the ROC curve (AUROC) of 0.752 (95% CI: 0.535 - 0.968, p = 0.033), indicating a statistically significant discriminatory ability. The best cut-off value, as determined with the Youden's J statistic, was 1.74 cm, with a sensitivity of 86% and specificity of 70% for predicting NIV requirement or inhospital death.

However, the number of events was low and the study was primarily powered for another outcome. Therefore, prospective validation is needed before we impose treatment based on this marker. In case the suggested ultrasound measurement (see introduction) proofs to be a discriminatory marker for deterioration during hospitalization or predictive of progression to Non-Invasive Ventilation, we hope to be able to perform a follow-up study in which patient will be randomized to either standard of care or 'elective' NIV (to avoid emergency NIV need) based on yet to determine cut-off values.

3.2 Design (including population, method, confounders and outcomes) A multi-center, prospective observational cohort study conducted at Isala Hospital and UMCG aimed at determining the value of the sonographic motion ratio (tidal/maximum) of the diaphragm in AECOPD after hospital admission. After enrollment, the sonographic diaphragm motion will be assessed as additional measurement during standard-of-care lung ultrasound (POCUS), after which hospital outcomes will be registered. Primary outcome will be the sensitivity of this ultrasound marker for in-hospital deterioration (progression to NIV of death). Secondary analysis will include predictive models.

3.3 Research question What is the sensitivity of the diaphragm motion ratio (tidal/maximum) during ultrasound for in-hospital deterioration (progression to NIV or death) in AECOPD.

Read the detailed description

See summary

02

Conditions studied

  • COPD

Keywords

  • diaphragm
  • ultrasound
  • COPD
03

In context

Pulmonary Disease, Chronic Obstructive

4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.

This study's planned enrollment of 186 is close to the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Isala is the lead sponsor of 36 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Hospitalized AECOPD patients

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Hospitalization primarily because of severe acute exacerbation of COPD
  • Spirometry record within last 5 years, with: post-bronchodilator FEV1/FVC \< 0,70 and FEV1% \< 80%predicted
  • Minimum of 10 packyears

Exclusion criteria

  • Exclusion criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Established diagnosis of diaphragm diaphragm paralysis.
  • Inability for diaphragm imaging (e.g. mechanical ventilation, or unable to follow vocal instructions).
  • Those not able or unwilling to give written informed consent.
  • Pregnant women
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
186 participants (estimated)
Patient registry
No

Groups and cohorts

  • study group

    Study group will receive ultrasound of the diaphragm on admission for acute exacerbation COPD. No further study interventions.

06

What researchers measure

Primary outcomes

  1. primary outcome

    The primary endpoint is the sensitivity of the diaphragm motion ratio (ultrasound marker) for predicting in-hospital deterioration (defined as progression to non-invasive ventilation or in-hospital death). Sensitivity will be calculated as: True Positives/(True Positives+False Negatives)

    Time frame: From enrollment to the end of hospitalization

07

Study locations

2 of 2 sites recruiting
  • Isala
    Zwolle, Overijssel 8025AB, Netherlands
    Recruiting
  • University Medical Centre Groningen
    Groningen, Provincie Groningen 9713GZ, Netherlands
    Recruiting
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 9, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259174
Lead sponsor
Isala
Responsible party
Wytze de Boer (MD, University Medical Center Groningen) — Principal investigator
First posted
Dec 2, 2025
Start date
Oct 14, 2025
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Wytze S de Boer, MD
Contact
w.s.de.boer@isala.nl
+31646312031

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion